A single dimension of general psychopathology, p, has been hypothesized to represent a general 29 liability that spans multiple types of psychiatric disorders and non-clinical variation in psychiatric 30 symptoms across the lifespan. We conducted genome-wide association analyses of lifetime 31 symptoms of mania, psychosis, irritability in 124,952 to 208,315 individuals from UK Biobank, 32 and then applied Genomic SEM to model the genetic relationships between these psychiatric 33 symptoms and clinically-defined psychiatric disorders (schizophrenia, bipolar disorder, major 34 depressive disorder). Two dimensions of cross-cutting genetic liability emerged: general 35 vulnerability to self-reported symptoms (p self ) versus transdiagnostic vulnerability to clinically-36 diagnosed disease (p clinician ). These were only modestly correlated (r g = .344). Multivariate GWAS 37 identified 145 and 11 independent and genome-wide significant loci for p clinician and p self , 38 respectively, and improved polygenic prediction, relative to univariate GWAS, in hold-out 39 samples. Despite the severe impairments in occupational and educational functioning seen in 40 patients with schizophrenia and bipolar disorder, p self showed stronger and more pervasive genetic 41 correlations with facets of socioeconomic disadvantage (educational attainment, income, and 42 neighborhood deprivation), whereas p clinician was more strongly associated with medical disorders 43 unrelated to the brain. Genetic variance in p clinician that was unrelated to general vulnerability to 44 psychiatric symptoms was associated with less socioeconomic disadvantage, suggesting positive 45 selection biases in clinical samples used in psychiatric GWAS. These findings inform criticisms 46 of psychiatric nosology by suggesting that cross-disorder genetic liabilities identified in GWASs 47 of clinician-defined psychiatric disease are relatively distinct from genetic liabilities operating on 48 self-reported symptom variation in the general population.
Introduction 50
Psychiatric nosology draws boundaries between normality and abnormality, and between 51 different types of abnormality (1,2). However, genome-wide association studies (GWASs) have 52 found that psychiatric disorders have a massively polygenic architecture, with near-ubiquitous 53 genetic correlations among them (3-5). These genetic correlations have motivated arguments that 54 current clinical boundaries are invalid, as they do not reflect the extensive overlap in underlying 55 genetic liabilities (5). Following McKusick's classic paper on the nosology of genetic diseases (6), 56
we term this the "lumping critique." Additionally, the polygenicity of psychiatric disorders has re-57 invigorated what we term the "dimensional critique": Clinically-defined disorders are alleged to 58 represent the extreme (and arbitrarily-defined) ends of quantitative dimensions of risk 59
encompassing the entire population (7-9). 60
Initiatives like the Research Domain Criteria (RDoC) (2), the Hierarchical Taxonomy of 61 Psychopathology (HiTOP) (10), and proposed revisions to the Diagnostic and Statistical Manual 62 of Mental Disorders (DSM-5) (11) have advanced both the lumping and the dimensional critiques, 63
arguing that the pathogenic processes underlying psychiatric disease cut across the boundaries 64 between different diagnostic entities and across the boundaries between normality and abnormality 65 (12). Perhaps the most radical expression of this view is the proposal that all forms of psychiatric 66 disease share a common set of pathogenic processes, which can be investigated using a latent 67 factor, p. The p factor has been conceptualized as representing a general liability to psychiatric 68 symptoms that cuts across diagnostic entities, across the range of symptom severity, and across 69 the lifespan (13, 14) . Although the lumping and the dimensional critiques are frequently advanced 70 together to challenge psychiatric nosology, they are separable. Psychiatric diseases might share 71 underlying pathogenic processes without those same processes operating throughout the entire 72 range of symptoms. 73
Moreover, debates about psychiatric nosology often implicitly assume that the same model 74 will be true for all forms of psychopathology, when, in fact, some diagnostic entities might be 75 better conceptualized as extreme ends of a continuous distribution than others (15-17). The 76 lumping and dimensional critiques of psychiatric nosology have been most hotly debated with 77 regard to schizophrenia and bipolar disorder (18) (19) (20) (21) (22) . Some theorists propose that disorders such 78
as schizophrenia and schizoaffective disorder should be replaced by a dimensional psychosis 79 spectrum (18, 19) . Proponents of this model argue that psychotic experiences, including mania, are 80 common in the general population and exhibit phenomenological and temporal continuity with 81 psychotic disorders (23,24). However, others have reported that psychotic experiences in the 82 general population share nonspecific, bi-directional associations with a wide range of mental 83 disorders (25-28) and can reflect misinterpretations of normative experiences (26). 84
The validity of the dimensional critique has also fed into debates about GWAS research 85 design. If valid, embracing "minimal phenotyping" in non-clinical samples has the potential to 86 accelerate genetic discovery via dramatic increases in sample size, as self-report survey measures 87 of psychiatric symptoms can be administered at scale to population-based or convenience samples. 88 In contrast, clinical-level pathology is currently demarcated not only by severity of symptoms, but 89 also by their co-occurrence within a specified timeframe. This requires a phenotypic approach that 90
can be slow, difficult, and costly. The argument for minimal phenotyping has been forwarded in 91 recent GWASs that have jointly analyzed clinically-defined depression phenotypes, depressive 92 symptoms, and related traits such as neuroticism and subjective well-being (8,29). Others have 93 argued, however, that minimal phenotyping might preferentially detect genetic variants that are 94 non-specific to any one disorder (30). 95
Previous efforts to use molecular genetic data to inform psychiatric nosology and GWAS 96 research design have typically addressed either the dimensional or the lumping critique, but not 97 both. Addressing the dimensional critique, previous studies have examined the genetic correlation 98 between a single clinically-defined disorder and normal-range symptom variation, e.g., between 99 attention-deficit hyperactivity disorder diagnoses and attention-deficit hyperactivity disorder 100 symptom counts (15). These studies, however, have not typically incorporated genetic data from 101 multiple clinically-defined diagnostic entities. Alternatively, addressing the lumping critique, 102 previous studies have documented genetic relationships among clinical-defined disorders (5) but 103
have not extensively probed the extent to which the genetic overlap among them can be projected 104 downward into the normal range of symptom variation. 105
The present paper addresses both the lumping and dimensional critiques by conducting a 106 multivariate GWAS of multiple clinically-defined disorders and of normal-range variation in these 107 disorders' cardinal symptoms. First, we conducted GWASs of lifetime symptoms of irritability, 108 mania, and psychosis in a population-based sample, and examine the pairwise genetic correlations 109 among these symptom dimensions, depressive symptoms, and lifetime diagnoses of serious 110 psychiatric disorders (schizophrenia, bipolar disorder, and major depressive disorder). Next, we 111 apply Genomic SEM (31) to test formal models of the genetic covariance among multiple 112 psychiatric disorders and symptom dimensions. 
Heritability and genetic correlation analyses 130
We used Linkage Disequilibrium (LD) Score regression to estimate heritabilities, 131 partitioned heritabilities, and genetic correlations among seven core phenotypes: symptoms of 132 irritability, mania, and psychosis, which were the focus of our novel GWASs; symptoms of 133 depression, which were analyzed in a previous large-scale GWAS (29); and three psychiatric 134 disorders (bipolar disorder, schizophrenia, major depressive disorder) (8,37,38) that are 135 characterized by these symptoms (Supplementary Note section 6). These GWASs and their 136 phenotypes are described in Table 1 . We also used LD Score regression to estimate genetic 137 correlations among the latent factors estimated in our Genomic SEM analyses and related traits. 138
Genomic structural equation modeling 139
Genomic SEM, a statistical method that provides a flexible framework for applying 140 structural equation modeling methods to GWAS results, was used to test a series of four 141 confirmatory factor models, which were informed by psychiatric and psychometric theory (31) Gene-wise analyses identified, after correcting for multiple testing, 25 significant genes 179 associated with mania and 25 associated with irritability (9 of which overlap across phenotypes; 180 Supplementary 
Multivariate GWAS of p factors 215
In multivariate GWAS testing associations between individual SNPs and latent factors, we 216 observed inflation of the median test statistic for both p clinician (λ GC = 1.585) and p self (λ GC = 1.403). 217
The estimated intercept from LD Score regression for p clinician and p self (0.9751 and 0.9911, 218 respectively) suggests that nearly all the inflation is due to polygenic signal rather than bias 219 (Figure 3) . Using the clumping procedure described in the Supplementary Note, we identified 145 220
and 11 approximately-independent lead SNPs for p clinician and p self , respectively (Supplementary 221 Table 22 ). 222
After correcting for multiple testing, gene-wise analyses identified 370 genes associated 223 with p clinician and 47 genes associated with p self (Supplementary Table 24 ). Sixty-two of the genes 224 associated with p clinician and twenty-one of the genes associated with p self can be considered novel, 225 as they were not associated with any of the constituent GWAS phenotypes. Moreover, only 11 226 genes were associated with both p factors. We discuss some of the genes associated with the p 227 factors in Supplementary Note section 9, such as RBFOX1. (Figure 4) . We observed a similar pattern of results in the 243 Philadelphia Neurodevelopmental Cohort (N = 4,551), where the p self polygenic score was 244 positively associated with a general factor of psychopathology constructed from self-report 245 measures (pseudo R 2 = 1.34%, P = 2.69E-13), while p clinician was not (Supplementary Table 32 ). 246
Exploring the divergent genetic architecture between p factors 247
We identified pervasive correlations between p self and worse cognitive performance, social 248 disadvantage, and accelerated reproductive development and mortality (Figure 4 ; Supplementary 249 Table 29) . Notably, p clinician shows a more consistent pattern of genetic correlations with medical 250 diagnoses unrelated to the brain, whereas p self appears to capture the genetic liability toward worse 251 social position more strongly than p clinician . To further probe the latter finding, we used Genomic 252 SEM to estimate the genetic correlations between the p factors and a latent genetic factor of general 253 social advantage, which captured genetic variance generally associated with social stratification in 254 educational attainment, income, and (reverse-coded) area-based social deprivation (41, 43 (Supplementary Figure 13) . This analysis estimated the genetic correlation 257 between social advantage and variance in p clinician that was distinct from p self. Additionally Second, psychiatric disorders are defined by combinations of symptoms that might be 295 heterogeneous with respect to genetic architecture, potentially attenuating the genetic correlation 296 with any one symptom. For instance, low genetic correlation between clinician-rated schizophrenia 297 and self-rated psychotic symptoms might be due to genetic influences on symptom domains not 298 assessed, such as negative symptoms. 299
Third, clinical assessment pays close attention to temporal frame during which symptoms 300 co-occur (Supplementary Figure 14) . In contrast, temporal clustering is not always considered in 301 self-reports of symptoms. In UK Biobank, for example, the assessment of mania refers to 302 symptoms that occur within a single period, but the measures of psychotic symptoms all refer to 303 lifetime occurrence. Little work has considered whether the genetic etiology of a symptoms that 304 occurs synchronously with another differs from the genetic etiology of that same symptom in 305 temporal isolation. 306
Fourth, people have unique insight into their own internal mental states, but they lack 307 perfect insight into how their behaviors are perceived by others, and they might be motivated to 308 diminish their symptoms because of social desirability biases. The relatively modest genetic 309 correlations between the p factors could reflect these asymmetries and biases. Moreover, some 310 symptoms (e.g., delusional thinking) themselves impair people's ability to report accurately on 311 their psychological experiences. 312
Finally, samples of people with clinician-rated disorders (particularly when those disorders 313 are rare and seriously impairing) are subject to different sources of selection, attrition, and non-314 response than population-based studies that utilize self-report surveys. Previous research has found 315 that genetic variants associated with educational attainment and schizophrenia predict research 316 participation (51,52). These selection processes could induce a collider bias, leading to misleading 317 estimates of genetic correlations (53). 318
We conducted an initial exploration of the potential role of selection bias by estimating the 319 unique genetic correlations between social advantage and both p factors. Although patients with 320 serious mental illness face severe educational and occupational impairments, we find that the 321 genetic variance unique to clinician-rated disorders was associated with less socioeconomic 322
disadvantage. This result suggests that patients represented in genetic association studies of 323 schizophrenia, bipolar disorder, and major depressive disorder might be positively selected for 324 social status. Consider, for instance, that incarcerated persons in Western countries are two-to 325 four-times more likely than the general population to have a psychotic disorder (54) , and the rate 326 of serious mental illness in homeless populations is about 20% (55), but these socially-327 marginalized groups are less likely to have access to adequate mental health care or be included in 328 medical research. At the same time, our GWASs of psychiatric symptoms rely on UK Biobank, a 329 volunteer sample that is generally healthier and more socially advantaged than the UK population 330 (56,57). As GWAS samples continue to grow, we expect that researchers will pay increasing 331 attention to issues around population representativeness. 332
In conclusion, current psychiatric nosology has been criticized for failing to account for 333 the ubiquitous genetic correlations among clinically-defined disorders and for embracing 334 categorical disease entities rather than continuous dimensions of risk. We conducted the first-ever 335 multivariate GWAS of multiple symptoms and disorders, and found that the genetic liabilities 336 operating on self-reported symptom variation were largely distinct from the genetic liabilities 337 operating on clinically-defined psychiatric diseases. These results refine criticisms of psychiatric 338 nosology and suggest that further research is needed to understand cross-cutting genetic risks. p clinician . The bottom panels (red) correspond to a Manhattan plot and a quantile-quantile plot for p self . In the Manhattan plots, the x-axis 511 refers to chromosomal position, the y-axis refers to the significance on a −log10 scale, and the horizontal dashed line marks the 512 threshold for genome-wide significance (P = 5×10 -8 ). In the quantile-quantile plots, the x-axis refers to expected P value, while the y-513 axis refers to the observed P value. . Follow-up analyses for p clinician and p self . In the leftmost panels, the predictive ability of p clinician and p self polygenic scores in 517 UKB holdout samples. In the rightmost panels, genetic correlations between p factors and phenotypes related to health, cognition, and 518 socioeconomic status. Error bars represent 95% confidence intervals. 519
